Blood Composition and Hemostasis

SECTION 1

Historical Context & Motivation

Blood has captivated physicians and natural philosophers for millennia, often regarded as the very essence of life itself. Ancient Greek physicians operating within the humoral tradition classified blood as one of four cardinal humors—alongside phlegm, yellow bile, and black bile—whose balance determined health and temperament. This framework, codified by Galen in the second century CE, dominated Western medicine for over a thousand years and led to the widespread practice of bloodletting as a therapeutic intervention. Although fundamentally incorrect in its mechanistic claims, humoral theory nonetheless recognized a crucial insight: blood is central to physiological homeostasis, and its perturbation has systemic consequences.

The scientific study of blood composition and clotting began to crystallize only with the advent of microscopy and experimental physiology. From the first description of red blood cells by Jan Swammerdam in the 1650s to the identification of clotting factors in the mid-twentieth century, our understanding of blood evolved from a vague vital fluid into a precisely characterized connective tissue with distinct formed elements, a complex plasma proteome, and an elaborate hemostatic cascade. This section traces the key milestones that shaped modern hematology.

1658

First Observation of Red Blood Cells

Jan Swammerdam used early microscopy to observe oval particles in frog blood, and shortly afterward, Antonie van Leeuwenhoek provided more detailed descriptions of human erythrocytes, launching the era of cellular hematology.

1842

Discovery of Platelets

Alfred Donné described small disc-shaped bodies in blood that were later recognized as platelets (thrombocytes) by Giulio Bizzozero in 1882, who demonstrated their role in thrombus formation at sites of vascular injury.

1905

The Classical Coagulation Cascade

Paul Morawitz proposed a four-factor model of coagulation involving thromboplastin, prothrombin, thrombin, and fibrinogen—laying the groundwork for the modern cascade model of hemostasis.

1964

Waterfall/Cascade Model Published

Macfarlane and Davie & Ratnoff independently proposed the enzyme cascade (waterfall) model of coagulation, describing intrinsic and extrinsic pathways that converge on a common pathway to generate fibrin.

2001

Cell-Based Model of Hemostasis

Maureane Hoffman and Dougald Monroe proposed the cell-based model, reframing coagulation as occurring in three overlapping phases—initiation, amplification, and propagation—on specific cell surfaces rather than as two independent cascades.

These advances raise a central question that this lesson addresses: how do the molecular and cellular constituents of blood coordinate to maintain fluid flow under normal conditions while rapidly sealing breaches in the vasculature? Answering this requires an integrated understanding of blood composition—its plasma, formed elements, and dissolved solutes—as well as the sequential mechanisms of hemostasis that prevent both hemorrhage and pathological thrombosis.

SECTION 2

Core Principles & Definitions

Blood is classified as a specialized connective tissue composed of a liquid extracellular matrix—plasma—and suspended cellular elements. An average adult circulates approximately 5 liters of blood, accounting for roughly 7–8% of total body weight. Blood performs three broad categories of function: transport (delivering O₂, nutrients, hormones, and removing CO₂ and metabolic waste), regulation (maintaining pH, temperature, and osmotic pressure), and protection (immune defense and hemostasis). Understanding these functions begins with a clear picture of what blood actually contains.

Plasma (≈55% of blood volume)

The straw-colored liquid matrix consisting of approximately 92% water, 7% plasma proteins (albumin, globulins, fibrinogen), and 1% dissolved solutes including electrolytes, nutrients, gases, and regulatory molecules.

Formed Elements (≈45%)

Erythrocytes (red blood cells), leukocytes (white blood cells), and thrombocytes (platelets). Erythrocytes dominate numerically at 4.5–5.5 million per µL, while leukocytes number 5,000–10,000/µL and platelets 150,000–400,000/µL.

Hematocrit

The percentage of blood volume occupied by erythrocytes after centrifugation. Normal ranges are 42–52% for males and 37–47% for females, reflecting differences in erythropoietin stimulation by androgens.

Hemostasis

The physiological process that stops bleeding at the site of vascular injury while maintaining normal blood flow elsewhere. It proceeds through three overlapping phases: vascular spasm, platelet plug formation, and coagulation.

Fibrinolysis

The regulated enzymatic dissolution of fibrin clots by plasmin, ensuring that hemostatic plugs are removed after tissue repair is complete and preventing pathological vessel occlusion.

✦ KEY TAKEAWAY

Think of blood as a carefully engineered highway system. Plasma is the road surface that carries everything; erythrocytes are the cargo trucks hauling oxygen and carbon dioxide; leukocytes are the patrol vehicles surveilling for threats; and platelets are the rapid-response repair crews that seal potholes (vascular injuries) the moment they form. Hemostasis is the coordinated emergency protocol that dispatches these repair crews, sets up barricades (the platelet plug), and pours fresh asphalt (fibrin mesh) to prevent the entire system from flooding—while simultaneously ensuring that the repaired road doesn't stay permanently blocked.

SECTION 3

Visual Explanation — Blood Composition

Figure 1 illustrates the three layers visible after centrifuging a blood sample: the yellow plasma supernatant (≈55%), a thin buffy coat containing leukocytes and platelets (<1%), and the dense erythrocyte pellet (≈45%). The erythrocyte fraction defines the hematocrit.

The diagram above captures the quantitative hierarchy of blood components. Erythrocytes are by far the most abundant formed element, outnumbering leukocytes by a factor of roughly 700:1. Their biconcave disc morphology maximizes the surface-area-to-volume ratio for efficient gas exchange and enables the flexible deformation required to pass through capillaries as narrow as 3 µm in diameter. Each erythrocyte contains approximately 280 million molecules of hemoglobin (Hb), a quaternary protein composed of two α-globin and two β-globin subunits, each complexed with an iron-containing heme group capable of reversibly binding one molecule of oxygen. The cooperative binding behavior of Hb produces the sigmoidal oxygen–hemoglobin dissociation curve that is critical for oxygen loading in the lungs and unloading in the tissues.

Plasma proteins deserve particular attention because they are integral to hemostasis. Albumin (≈54% of plasma protein) maintains colloid osmotic pressure and serves as a carrier protein. Globulins (≈38%) include immunoglobulins (antibodies) and transport globulins. Fibrinogen (≈7%) is the soluble precursor to fibrin and is essential for the coagulation cascade. When fibrinogen and other clotting factors are removed from plasma, the remaining fluid is termed serum.

SECTION 4

The Three Phases of Hemostasis

Hemostasis—from the Greek haima (blood) and stasis (standing still)—is not a single event but a precisely orchestrated sequence of three overlapping phases. Each phase builds on the previous one, amplifying the hemostatic response until a stable clot forms. It is useful to consider these phases as a continuum rather than discrete steps, since platelet activation and coagulation factor activation occur simultaneously and reinforce each other through positive feedback loops.

Phase 1: Vascular Spasm

The immediate response to vascular injury is vascular spasm (vasoconstriction), which narrows the damaged vessel and reduces blood flow to the area. This spasm is triggered by direct injury to vascular smooth muscle, reflexes initiated by local pain receptors, and chemical mediators such as endothelin released from damaged endothelial cells and thromboxane A₂ (TXA₂) released from activated platelets. In small vessels, vascular spasm alone may be sufficient to stop bleeding; in larger vessels, it merely slows blood loss long enough for subsequent phases to occur.

Phase 2: Platelet Plug Formation (Primary Hemostasis)

Within seconds of endothelial disruption, subendothelial collagen is exposed to the flowing blood. Platelets adhere to this collagen through a bridging molecule called von Willebrand factor (vWF), which binds simultaneously to collagen fibers and the platelet surface receptor glycoprotein Ib (GPIb). This initial adhesion triggers platelet activation, causing the platelets to change shape from smooth discs to spiky spheres, degranulate (releasing ADP, serotonin, and TXA₂), and express the integrin receptor GPIIb/IIIa on their surfaces. GPIIb/IIIa binds fibrinogen, which cross-links adjacent platelets and recruits additional platelets in a positive feedback loop, forming the platelet plug.

Phase 3: Coagulation Cascade (Secondary Hemostasis)

The platelet plug is reinforced by a mesh of fibrin generated through the coagulation cascade—a series of enzymatic reactions in which inactive zymogens (proenzymes) are sequentially activated. The cascade is traditionally described in terms of two convergent pathways. The extrinsic (tissue factor) pathway is initiated when tissue factor (TF, factor III) released from damaged cells binds factor VII in the presence of Ca²⁺ to form the TF–VIIa complex. The intrinsic (contact activation) pathway begins when factor XII is activated upon contact with exposed collagen or negatively charged surfaces. Both pathways converge at the activation of factor X, which, in complex with factor Va, Ca²⁺, and platelet phospholipids (the prothrombinase complex), converts prothrombin (factor II) to thrombin (factor IIa). Thrombin then cleaves fibrinogen into fibrin monomers, which polymerize and are cross-linked by factor XIIIa into a stable fibrin mesh.

COMMON PATHWAY SUMMARY

Factor Xa + Factor Va + Ca²⁺ + PL → Prothrombinase → Prothrombin → Thrombin → Fibrinogen → Fibrin

PL = platelet phospholipids. Each arrow represents an enzymatic conversion. Factor XIIIa cross-links soluble fibrin monomers into an insoluble fibrin polymer mesh.

💊 Clinical Note: Anticoagulant Targets

Understanding the cascade helps explain drug mechanisms. Warfarin inhibits vitamin K–dependent synthesis of factors II, VII, IX, and X. Heparin potentiates antithrombin III, which inhibits thrombin and factor Xa. Newer direct oral anticoagulants (DOACs) such as rivaroxaban selectively inhibit factor Xa, while dabigatran directly inhibits thrombin.

SECTION 5

The Coagulation Cascade — Detailed Breakdown

Figure 2: The classical coagulation cascade. The intrinsic pathway (left, assessed by aPTT) begins with contact activation of factor XII. The extrinsic pathway (right, assessed by PT/INR) begins with tissue factor release. Both converge on the common pathway at factor X, ultimately generating fibrin.

Several features of the cascade deserve emphasis. First, it is a biological amplification system: a small amount of tissue factor can ultimately generate an enormous burst of thrombin because each activated enzyme catalyzes the activation of many molecules of the next factor in the series. Second, many steps require Ca²⁺ ions and phospholipid surfaces provided by activated platelets, which is why EDTA and citrate (calcium chelators) are effective anticoagulants in vitro. Third, thrombin is the master enzyme of coagulation: in addition to converting fibrinogen to fibrin, thrombin activates factors V, VIII, XI, and XIII, and stimulates platelet aggregation—establishing the powerful positive feedback loops that ensure rapid clot formation.

Selected coagulation factors and their roles

Factor	Common Name	Pathway	Function
I	Fibrinogen	Common	Converted to fibrin by thrombin
II	Prothrombin	Common	Converted to thrombin by prothrombinase
III	Tissue Factor (TF)	Extrinsic	Initiates extrinsic pathway by binding VII
VII	Proconvertin	Extrinsic	Forms TF–VIIa complex; activates X
X	Stuart–Prower factor	Common	Key convergence point; forms prothrombinase with Va
XIII	Fibrin-stabilizing factor	Common	Cross-links fibrin monomers into stable polymer

SECTION 6

Worked Example — Interpreting a Coagulation Panel

A key clinical application of hemostasis knowledge is interpreting coagulation laboratory results. Consider the following scenario: a 62-year-old patient presents with easy bruising and prolonged bleeding after minor cuts. A complete blood count (CBC) and coagulation panel are ordered.

Interpreting Coagulation Lab Values

Step 1 — Identify the Given Laboratory ValuesThe patient's results are: Platelet count = 210,000/µL (normal: 150,000–400,000/µL); PT = 24.5 seconds (normal: 11–13.5 s); INR = 2.1 (normal: 0.8–1.1 for unmedicated patients); aPTT = 32 seconds (normal: 25–35 s). Begin by comparing each value to its reference range.

Platelet count: normal. PT/INR: prolonged/elevated. aPTT: normal.

Step 2 — Determine Which Pathway Is AffectedRecall that PT (prothrombin time) assesses the extrinsic and common pathways (factors VII, X, V, II, and fibrinogen), while aPTT (activated partial thromboplastin time) assesses the intrinsic and common pathways (factors XII, XI, IX, VIII, X, V, II, fibrinogen). An isolated prolongation of PT with a normal aPTT points to a deficiency or inhibition of a factor unique to the extrinsic pathway.

The defect is isolated to the extrinsic pathway → Factor VII is the sole unique factor.

Step 3 — Formulate a Differential DiagnosisAn isolated PT prolongation suggests factor VII deficiency or inhibition. Factor VII has the shortest half-life (≈6 hours) of all the vitamin K–dependent factors, so it is the first to decline in early vitamin K deficiency, early liver disease, or the initial phase of warfarin therapy. Given the patient's INR of 2.1, one should inquire whether the patient is taking warfarin, has dietary vitamin K deficiency, or has hepatic dysfunction.

Most likely causes: warfarin therapy, early vitamin K deficiency, or early hepatic synthetic failure.

Step 4 — Correlate with Clinical ContextUpon further history, the patient reveals they were recently started on warfarin for atrial fibrillation. The target INR for non-valvular atrial fibrillation is typically 2.0–3.0. The patient's INR of 2.1 is within the therapeutic range, indicating that the drug is working as intended. The easy bruising is an expected side effect at therapeutic anticoagulation levels and should be monitored rather than treated, unless clinically significant bleeding occurs.

Conclusion: PT/INR prolongation is consistent with therapeutic warfarin anticoagulation. No immediate intervention required; continue monitoring.

🩺 CLINICAL REASONING TIP

When interpreting coagulation panels, use a systematic approach: first check platelet count (primary hemostasis), then PT (extrinsic/common), then aPTT (intrinsic/common). If only one test is abnormal, the defect lies in the pathway unique to that test. If both PT and aPTT are prolonged, suspect a common pathway defect (factor X, V, II, or fibrinogen) or a systemic condition such as DIC or severe liver disease.

SECTION 7

Anticoagulant Mechanisms & Hemostatic Disorders

Hemostasis is a double-edged sword: too little clotting leads to hemorrhage, while too much leads to thrombosis. The body maintains a delicate balance through a suite of endogenous anticoagulant mechanisms that confine clot formation to the site of injury and prevent systemic coagulation. Understanding these regulatory mechanisms is essential for appreciating both normal physiology and the pathophysiology of bleeding and thrombotic disorders.

Endogenous anticoagulant and fibrinolytic mechanisms

Mechanism	Action	Clinical Relevance
Antithrombin III (AT-III)	Serine protease inhibitor that inactivates thrombin, Xa, IXa, and XIa; activity dramatically enhanced by heparin	AT-III deficiency → increased venous thromboembolism risk; heparin therapeutic target
Protein C / Protein S	Thrombin–thrombomodulin complex on endothelial surfaces activates Protein C, which (with cofactor Protein S) inactivates factors Va and VIIIa	Factor V Leiden mutation renders factor Va resistant to Protein C → most common inherited thrombophilia
Tissue Factor Pathway Inhibitor (TFPI)	Inhibits TF–VIIa complex and factor Xa, limiting the initiation phase of the extrinsic pathway	Prevents runaway activation of the extrinsic pathway beyond the injury site
Prostacyclin (PGI₂) & Nitric Oxide (NO)	Released by intact endothelium; PGI₂ inhibits platelet aggregation; NO causes vasodilation and inhibits platelet adhesion	Endothelial dysfunction (e.g., atherosclerosis) reduces PGI₂/NO → prothrombotic state
Fibrinolysis (Plasmin)	Tissue plasminogen activator (tPA) converts plasminogen → plasmin, which degrades fibrin into fibrin degradation products (FDPs, including D-dimer)	Elevated D-dimer used clinically to screen for DVT/PE; tPA administered as thrombolytic in acute MI and stroke

✦ KEY TAKEAWAY

The hemostatic system operates like a sophisticated thermostat with multiple feedback loops. Just as a thermostat must both heat and cool a building to maintain a set temperature, the body must balance procoagulant forces (the cascade, platelet activation) against anticoagulant forces (antithrombin, Protein C/S, fibrinolysis) to maintain blood fluidity. Disease states represent thermostat malfunctions: hemorrhagic disorders arise when procoagulant activity is insufficient (e.g., hemophilia, thrombocytopenia), and thrombotic disorders arise when anticoagulant mechanisms fail (e.g., Factor V Leiden, antiphospholipid syndrome).

SECTION 8

Connection to Advanced Topics & Integrative Physiology

The classical cascade model presented in this lesson, while clinically useful for interpreting coagulation tests (PT and aPTT map neatly onto the extrinsic and intrinsic pathways, respectively), is an oversimplification of in vivo hemostasis. The cell-based model of coagulation provides a more physiologically accurate framework by emphasizing that coagulation occurs on specific cell surfaces in three overlapping phases: initiation (on tissue factor–bearing cells), amplification (on platelet surfaces, generating small amounts of thrombin), and propagation (on activated platelet surfaces, generating the thrombin burst). This model better explains why patients with factor XII deficiency do not bleed (factor XII is not essential for in vivo hemostasis) and why hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) produce severe bleeding despite these factors being in the 'intrinsic' pathway.

Classical cascade model vs. cell-based model of coagulation

Feature	Classical Cascade Model	Cell-Based Model
Organization	Two independent pathways (intrinsic + extrinsic) converging on a common pathway	Three overlapping phases (initiation, amplification, propagation) on specific cell surfaces
Primary value	Interpreting in vitro coagulation tests (PT, aPTT)	Explaining in vivo coagulation physiology and pathology
Role of factor XII	Initiates the intrinsic pathway	Minimal role in physiological hemostasis; important in pathological thrombosis
Cell surfaces	Phospholipids mentioned but cells not central	TF-bearing cells and activated platelets are essential platforms for each phase
Clinical application	Standard lab interpretation; monitoring warfarin and heparin	Guiding development of novel hemostatic agents; understanding DIC and sepsis-associated coagulopathy

Beyond the coagulation cascade itself, blood composition and hemostasis connect to numerous advanced topics you will encounter in upper-division courses and clinical training. Disseminated intravascular coagulation (DIC) represents pathological activation of the coagulation system throughout the vasculature, consuming platelets and clotting factors and paradoxically causing both thrombosis and hemorrhage. Hematopoiesis in the bone marrow involves cytokine-driven differentiation of pluripotent stem cells into all blood cell lineages, regulated by erythropoietin (RBCs), thrombopoietin (platelets), and colony-stimulating factors (WBCs). Understanding these connections will prepare you to integrate hemostatic physiology with immunology, pharmacology, and clinical medicine.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A patient has a normal platelet count, normal PT/INR, but a prolonged aPTT. Which segment of the coagulation cascade is most likely affected, and which specific clotting factor deficiency would you consider first in a male patient with a history of joint bleeding (hemarthrosis)?

PROBLEM 2 — BASIC CALCULATION

A patient's CBC reveals the following: total blood volume = 5.2 L, hematocrit = 0.48 (48%). Calculate the volume of plasma and the volume of packed erythrocytes in this patient. If the patient's hemoglobin concentration is 16 g/dL, how many total grams of hemoglobin are circulating?

PROBLEM 3 — INTERMEDIATE

Explain why blood collected in a tube containing EDTA (ethylenediaminetetraacetic acid) does not clot. Relate your answer to the role of calcium ions in the coagulation cascade, specifying at least two points in the cascade where Ca²⁺ is required.

PROBLEM 4 — APPLIED

A 70-year-old patient on warfarin therapy for deep vein thrombosis (DVT) prophylaxis presents with an INR of 5.8 (therapeutic target: 2.0–3.0) and melena (dark, tarry stools indicating GI bleeding). Explain the pharmacological basis of warfarin's mechanism, why an INR of 5.8 is dangerous, and outline the immediate corrective measures a clinician would consider.

PROBLEM 5 — CRITICAL THINKING

Disseminated intravascular coagulation (DIC) is sometimes described as a 'paradox' because patients experience both thrombosis and hemorrhage simultaneously. Using your knowledge of the coagulation cascade, platelet plug formation, fibrinolysis, and anticoagulant regulation, construct a mechanistic explanation for how this paradox arises. Include the role of D-dimer in the diagnostic workup.

SUMMARY

Lesson Summary

Blood is a specialized connective tissue comprising plasma (≈55%) and formed elements (≈45%), with erythrocytes dominating the cellular fraction. Plasma contains water, albumin, globulins, fibrinogen, electrolytes, and dissolved gases. The hematocrit quantifies the erythrocyte fraction and reflects oxygen-carrying capacity.

Hemostasis proceeds through three overlapping phases: vascular spasm (vasoconstriction), platelet plug formation (primary hemostasis, involving vWF, GPIb, and GPIIb/IIIa), and the coagulation cascade (secondary hemostasis). The cascade features intrinsic and extrinsic pathways converging on a common pathway that generates thrombin and ultimately converts fibrinogen to fibrin. Endogenous anticoagulants (antithrombin III, Protein C/S, TFPI) and fibrinolysis (plasmin degrading fibrin into D-dimer) prevent pathological thrombosis and ensure clots are removed after tissue repair. Mastery of these concepts is foundational for pharmacology, clinical medicine, and pathophysiology coursework.